Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Recruiting 3Not yet recruiting 3Completed 2Unknown 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 1C-Met Exon 14 Mutation 1Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors 1

Interventions

pembrolizumab 567Specimen Handling 487Carboplatin 456Magnetic Resonance Spectroscopy 442Cyclophosphamide 418Cisplatin 412Radiotherapy 353Gemcitabine 318Bevacizumab 317Paclitaxel 304Biopsy 291Drug Therapy 286Blood Specimen Collection 249Capecitabine 244Oxaliplatin 242fludarabine 238Nivolumab 236venetoclax 227Injections 214Docetaxel 209Fluorouracil 204Dexamethasone 187Radiosurgery 182Rituximab 162Pemetrexed 160Standard of Care 156Surgical Procedures, Operative 148durvalumab 146atezolizumab 146tislelizumab 140

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × glumetinib × Clear all
NCT06947291 2025-09-08

Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2 Recruiting
350 enrolled
GastrointestinalOther solid neoplasm

Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors

NCT06829459 2025-04-08

A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs

Shanghai JMT-Bio Inc.

Phase 3 Recruiting
350 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04270591 2022-08-01

Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

Haihe Biopharma Co., Ltd.

Phase 1/2 Recruiting
183 enrolled

C-Met Exon 14 Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡